Imperial College London
Dr Aarif O Eifan

Dr Aarif O Eifan

Faculty of Medicine, National Heart & Lung Institute

Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 3164a.eifan Website

 
 
//

Location

 

Royal BromptonRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Penagos:2018:10.1007/s40521-018-0176-2,
author = {Penagos, M and Eifan, AO and Durham, SR and Scadding, GW},
doi = {10.1007/s40521-018-0176-2},
journal = {Current Treatment Options in Allergy},
pages = {275--290},
title = {Duration of allergen immunotherapy for long-term efficacy in allergic rhinoconjunctivitis},
url = {http://dx.doi.org/10.1007/s40521-018-0176-2},
volume = {5},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - RationaleSubcutaneous and sublingual immunotherapy are effective for allergic rhinitis. An important question is whether allergen immunotherapy provides a sustained clinical effect after treatment cessation. In view of potential side effects, cost and the necessary patient commitment, long-term benefit is an important consideration for the recommendation of immunotherapy over standard pharmacotherapy.Purpose of reviewIn this review, we analyse the existing evidence for long-term effects of both routes of administration in the context of double-blind, placebo-controlled, randomised clinical trials that included a follow-up phase of at least 1 year after treatment cessation.Recent findingsOverall, evidence suggests that 3 years of either subcutaneous or sublingual immunotherapy result in clinical benefit and immunological changes consistent with allergen-specific tolerance sustained for at least 2–3 years after treatment cessation.SummaryThe data presented here support recommendations in international guidelines that both routes of administration should be continued for a minimum of 3 years. Gaps in the evidence remain regarding the long-term efficacy of immunotherapy for perennial rhinitis and studies performed in children.
AU  - Penagos,M
AU  - Eifan,AO
AU  - Durham,SR
AU  - Scadding,GW
DO  - 10.1007/s40521-018-0176-2
EP  - 290
PY  - 2018///
SN  - 2196-3053
SP  - 275
TI  - Duration of allergen immunotherapy for long-term efficacy in allergic rhinoconjunctivitis
T2  - Current Treatment Options in Allergy
UR  - http://dx.doi.org/10.1007/s40521-018-0176-2
UR  - http://hdl.handle.net/10044/1/64310
VL  - 5
ER  -
Download